Popular on EntSun
- Female Motorsports Sponsorship & Expansion; Acquisition Agreement of UAE-Based Sports Incubator by Online Lottery & Sports Game Provider: Lottery.com - 234
- Experience Trembling Firsthand with the New AgeMan® Tremor Simulator - 216
- WOA Entertainment Group Unveils Independent No.1's: Breakthrough Artists II —A Celebration of Indie Excellence - 214
- Edtech Startup Young Commanders Launches 'Visionaries Without Sight' Collection Celebrating Blind and Visually Impaired Historical Figures - 208
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement - 177
- Let's Talk Series: At the Crossroads: Immigration Today - 156
- Token-Operated Sake Service Opens at Tobu Nikko Station - 126
- Honoring Black History, Culture, and Community in Fall River - 123
- BillBoards Inc. Hits the Road with God Bless America Tour and Reality Series Now Streaming on Tubi TV - 113
- databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research - 112
Similar on EntSun
- SacraPod Suites Unveils AI-Powered 'Work + Rest' Smart Hospitality Model for Retrofitting Underused Motels Across the U.S
- New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
- $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
- West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
- Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
- New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
- Digital Watchdog Launches New myDW Cloud Services
- AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
- Retired Hobbyist Launches Bold Weekly Album Project Using AI Songwriting Tools
- Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
OncoBeta ® GmbH Named Among '30 Ethical Companies of the Year 2019' by The Silicon Review Magazine
EntSun News/10771722
Recognition for OncoBeta`s mission to give non-melanocytic skin cancer patients back their quality of life.
MUNICH, Germany - April 5, 2019 - EntSun -- April 05, 2019; Garching near Munich, Germany - OncoBeta® GmbH, a Medical Device Company specialized in innovative epidermal radioisotope therapies for Non-Melanocytic Skin Cancer (NMSC) proudly announced today that the Silicon Review Magazine has named it among the 30 Ethical Companies of the Year 2019.
"The Silicon Review 30 Ethical Companies of the Year 2019 program identifies companies that are not only financially successful but also are among the most ethical. Winning a spot on this list indicates the company has distinguished itself as an ethically-driven organization," said Sreshtha Banerjee, Editor-in-Chief of The Silicon Review Magazine. The publication has selected OncoBeta® GmbH based on its culture of learning, strong ethical leadership, integrity and fairness, and moreover, the ability to maintain their global business conduct.
"We adhere to a high level of core values in our doings, focusing on providing the best products possible for patients and physicians." states Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH "It is an honor for us to be recognized and featured in this prominent publication for our work ethics and principles that govern our behavior on how we conduct our business."
With the patient in focus, OncoBeta works enthusiastically with medical, scientific, and industrial partners as well as local and national authorities to make his personalized, painless and non-invasive Rhenium-SCT® therapy accessible to patients all over the world.
The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. To serve the increasing medical need for innovative therapies in this field and to improve the quality of patients' lives, OncoBeta® GmbH has developed its innovative Rhenium-SCT® which only require a single application, applied in one single session with excellent aesthetic outcomes.
More on EntSun News
View the complete list of the Top 30 Ethical Companies 2019 in the digital Silicon Review magazine here:
https://thesiliconreview.com/magazines/magazine_profile.php?id=181&page=3
Read Silicon Review's exclusive interview with Shannon D. Brown III, CEO and Managing Director of OncoBeta GmbH here:
https://thesiliconreview.com/magazines/the-pioneers-and-innovators-in-the-epidermal-radioisotope-therapy-sector-oncobeta-gmbh/
About the Rhenium-SCT® (Skin Cancer Therapy)
The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium- SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium- SCT® compound never comes in direct contact with the patients' skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.
About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. OncoBeta® GmbH is European CE certified and has filed for regulatory approval in several other countries outside the European Union.
More on EntSun News
Furthermore, having the patient in focus, OncoBeta® is enthusiastically working with medical, scientific and industrial partners as well as local and national authorities to make this personalized, painless and non-invasive therapy accessible to patients all over the world. The Rhenium-SCT® significantly improves outcomes and the quality of life of non-melanoma skin cancer patients.
Find out more about the Rhenium-SCT® at https://www.oncobeta.com
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/OncoBeta/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta®'s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta®'s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
END
"The Silicon Review 30 Ethical Companies of the Year 2019 program identifies companies that are not only financially successful but also are among the most ethical. Winning a spot on this list indicates the company has distinguished itself as an ethically-driven organization," said Sreshtha Banerjee, Editor-in-Chief of The Silicon Review Magazine. The publication has selected OncoBeta® GmbH based on its culture of learning, strong ethical leadership, integrity and fairness, and moreover, the ability to maintain their global business conduct.
"We adhere to a high level of core values in our doings, focusing on providing the best products possible for patients and physicians." states Shannon D. Brown III, CEO and Managing Director of OncoBeta® GmbH "It is an honor for us to be recognized and featured in this prominent publication for our work ethics and principles that govern our behavior on how we conduct our business."
With the patient in focus, OncoBeta works enthusiastically with medical, scientific, and industrial partners as well as local and national authorities to make his personalized, painless and non-invasive Rhenium-SCT® therapy accessible to patients all over the world.
The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. Depending on the source, it is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. To serve the increasing medical need for innovative therapies in this field and to improve the quality of patients' lives, OncoBeta® GmbH has developed its innovative Rhenium-SCT® which only require a single application, applied in one single session with excellent aesthetic outcomes.
More on EntSun News
- New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
- Couture By Elesia Reclaims The Runway Of Everyday Life With Bold Return And New Hiya Sunshine Line
- BillBoards Inc. Hits the Road with God Bless America Tour and Reality Series Now Streaming on Tubi TV
- Cynthia Pinot Among Artists Selected for Renowned London Art Biennale 2025
- Real Estate Experts Highlight Jersey Shore as a Smart Buy in 2025
View the complete list of the Top 30 Ethical Companies 2019 in the digital Silicon Review magazine here:
https://thesiliconreview.com/magazines/magazine_profile.php?id=181&page=3
Read Silicon Review's exclusive interview with Shannon D. Brown III, CEO and Managing Director of OncoBeta GmbH here:
https://thesiliconreview.com/magazines/the-pioneers-and-innovators-in-the-epidermal-radioisotope-therapy-sector-oncobeta-gmbh/
About the Rhenium-SCT® (Skin Cancer Therapy)
The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium- SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium- SCT® compound never comes in direct contact with the patients' skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.
About OncoBeta® GmbH
OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. OncoBeta® GmbH is European CE certified and has filed for regulatory approval in several other countries outside the European Union.
More on EntSun News
- Slipaway Food Truck Park & Marina announces opening weekend July 4-6
- 16-Year-Old Entrepreneur Discovers All-Natural Skincare Breakthrough That Works in Just 48 Hours
- Collision Course Concert Series Returns to Atlanta
- $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
- West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
Furthermore, having the patient in focus, OncoBeta® is enthusiastically working with medical, scientific and industrial partners as well as local and national authorities to make this personalized, painless and non-invasive therapy accessible to patients all over the world. The Rhenium-SCT® significantly improves outcomes and the quality of life of non-melanoma skin cancer patients.
Find out more about the Rhenium-SCT® at https://www.oncobeta.com
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/
Facebook: https://www.facebook.com/OncoBeta/
Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta®'s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta®'s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
END
Source: OncoBeta GmbH
Filed Under: Technology
0 Comments
Latest on EntSun News
- AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
- Construcción del Corredor Norte–Sur (NSC) de Singapur
- New Report: Slip and Fall Accidents Rank as the Leading Cause of Construction Site Fatalities
- Get Your Cowboy Boots On! Causeway Country BBQ Music Festival Kicks Off September 12–14 in Ft. Pierce
- Retired Hobbyist Launches Bold Weekly Album Project Using AI Songwriting Tools
- DimHum Launches Revolutionary CrowdShipping Service
- Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
- Jekale (JK) Debuts R-B Single "Jungle" Inspired by Fashion, Storytelling, and Self-Discovery
- Favorite Wedding Décor Ideas to Inspire Your Big Day: From Vision to Venue
- Infinite Health Introduces Cutting-Edge Regenerative Medicine for Wound Care with Trip Goolsby, MD
- Riser Music's LYKN Adds India, Mexico & U.s. Dates To "unleashed" World Tour
- A Theatrical Experience Like No Other: "A Praying Mama, A Rebellious Son" Comes August 30
- Prolific Hollywood Actor Phillip E. Walker-MFA is Experiencing His Best Year of Employment Ever
- Top Dentist Concord CA, Smile Makers Dental Care, Celebrates 500 5-Star Reviews
- Bio-Inspired Technology-Dynamic and Adaptable for unknown real-world environments
- ALIVE and KICKING: LAUGHTER NEVER GETS OLD has its World Premiere July 11-20 in St. Charles, IL
- Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
- Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
- Live Courageously Hosts Ann-Marie Murrell, Author, Journalist, Former Political Commentator
- $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments